Plasma Fractionation Market

The plasma fractionation market is projected to reach USD 52.58 billion by 2031 from USD 36.44 billion in 2026, at a CAGR of 7.6% during the forecast period.

CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (US), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (US), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India) are the key players in this market.

To know about the assumptions considered for the study download the pdf brochure

These market players have adopted various strategies, including capacity expansions, strategic alliances, manufacturing investments, product launches, and supply agreements, to strengthen their positions in the plasma fractionation market. In November 2025, CSL announced plans to invest approximately USD 1.5 billion in the US over five years to expand manufacturing of plasma-derived therapies and to strengthen domestic production capacity.

In June 2024, Takeda Pharmaceutical Company Limited announced a USD 230 million expansion of its Los Angeles plasma-derived therapies manufacturing site, which is expected to add up to 2 million liters of annual plasma fractionation capacity. In July 2025, Grifols, S.A. announced a EUR 160 million investment in a new facility in Spain, expected to double its plasma fractionation capacity in Europe.

CSL (Australia): CSL offers a broad portfolio of plasma-derived therapies, including immunoglobulins, albumin, coagulation factor concentrates, and other plasma-derived products. Its vertically integrated operations span plasma collection, fractionation, manufacturing, and distribution, supporting the supply of therapies for immunology, neurology, hematology, and critical care. The company continues to expand plasma collection and manufacturing capacity to strengthen the supply of plasma-derived therapies and improve regional availability.

Grifols, S.A. (Spain): Grifols has an integrated business focused on plasma-derived products, spanning plasma collection, fractionation, manufacturing, and distribution. Its portfolio includes immunoglobulins, albumin, coagulation factor concentrates, and other plasma-derived products used across immunology, neurology, hematology, critical care, and pulmonology. In July 2025, Grifols announced a EUR 160 million investment in a new manufacturing facility in Spain, which is expected to double its European plasma fractionation capacity.

Takeda Pharmaceutical Company Limited (Japan): Takeda participates in the plasma fractionation market through its portfolio of plasma-derived therapies, including immunoglobulins, albumin, and other plasma-derived products. The company operates integrated plasma collection, fractionation, and manufacturing capabilities that support therapeutic applications across immunology, neurology, hematology, and other disease areas. In June 2024, Takeda announced a USD 230 million expansion of its Los Angeles manufacturing site for plasma-derived therapies, expected to add up to 2 million liters of annual plasma fractionation capacity.

Market Ranking

The plasma fractionation market is highly consolidated, with leading companies driving innovation, capacity expansion, and adoption. CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), and Grifols, S.A. (Spain) are the leading players in the market. CSL operates an integrated plasma collection and fractionation network, offering plasma-derived products across immunology, neurology, hematology, and critical care. Takeda Pharmaceutical Company Limited offers a broad portfolio of plasma-derived therapies and has expanded its plasma fractionation and manufacturing capacity across key markets. Grifols, S.A. operates an integrated plasma collection, fractionation, and manufacturing network and offers immunoglobulins, albumin, coagulation factor concentrates, and other plasma-derived products. Together, these companies maintain substantial plasma collection infrastructure and fractionation capacity, supporting their strong presence in the global plasma fractionation market.

Related Reports:

Plasma Fractionation Market by Product (Immunoglobulins [Intravenous, Subcutaneous], Albumin, Protease Inhibitors, VWF), Application (Preclinical, Therapeutics), Therapy (Neurology, Immunology, Hematology, Rheumatology), Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]